高级搜索

缺氧相关的miRNA-210在肿瘤中的研究进展

曹铮, 冯林, 冯晓莉

曹铮, 冯林, 冯晓莉. 缺氧相关的miRNA-210在肿瘤中的研究进展[J]. 肿瘤防治研究, 2018, 45(7): 500-504. DOI: 10.3971/j.issn.1000-8578.2018.17.1457
引用本文: 曹铮, 冯林, 冯晓莉. 缺氧相关的miRNA-210在肿瘤中的研究进展[J]. 肿瘤防治研究, 2018, 45(7): 500-504. DOI: 10.3971/j.issn.1000-8578.2018.17.1457
CAO Zheng, FENG Lin, FENG Xiaoli. Research Advance of Hypoxia-regulated miR-210 in Cancer[J]. Cancer Research on Prevention and Treatment, 2018, 45(7): 500-504. DOI: 10.3971/j.issn.1000-8578.2018.17.1457
Citation: CAO Zheng, FENG Lin, FENG Xiaoli. Research Advance of Hypoxia-regulated miR-210 in Cancer[J]. Cancer Research on Prevention and Treatment, 2018, 45(7): 500-504. DOI: 10.3971/j.issn.1000-8578.2018.17.1457

缺氧相关的miRNA-210在肿瘤中的研究进展

详细信息
    作者简介:

    曹铮(1993-),女,硕士在读,主要从事肿瘤病理学研究

    通讯作者:

    冯晓莉,E-mail: fengxl@hotmail.com

  • 中图分类号: R730.2

Research Advance of Hypoxia-regulated miR-210 in Cancer

More Information
  • 摘要:

    肿瘤组织失控性增殖及其内部新生血管网的相对不足导致氧气供应不足,低氧是肿瘤微环境的重要特征,低氧环境可激活肿瘤细胞中低氧诱导因子(hypoxia-inducible factors, HIFs)的表达并诱导一系列miRNAs(microRNAs, miRs)含量发生变化。miRNA是一种小的、非编码RNA,可和mRNA 3’端非编码区结合,在转录后水平调节基因的表达,miR-210作为最主要的HIFs诱导表达的miRNA,参与肿瘤细胞多种生命活动,如肿瘤细胞线粒体代谢、血管形成、细胞周期调节、DNA断裂修复等;miR-210在大部分肿瘤患者的血清及肿瘤组织中高表达,且miR-210的表达水平与不良预后呈正相关,故miR-210可用于肿瘤的筛查、诊断和预测患者预后;随着对miR-210下游靶基因的深入研究,针对miR-210细胞信号转导通路的靶向治疗可为恶性肿瘤的治疗提供更广阔的前景。

     

    Abstract:

    The uncontrolled proliferation of tumor cells and the relative deficiency of the internal neovascularization network lead to insufficient oxygen supply. Hypoxia, an important feature of tumor microenvironment, can active the expression of hypoxia-inducible factors(HIFs) and induce the change of a number of miRNAs (microRNAs, miRs) content. miRNA are small, noncoding RNA, regulating gene expression mainly at post-transcriptional level. miR-210 have an important role in the occurrence and development of tumors as the most principal hypoxia-regulated-miRNAs, participating in cell activities such as mitochondrial metabolism, angiogenesis, cell cycle regulation, DNA repair and so on; miR-210 is over-expressed in most tumor tissues and plasma, and correlated with poor prognosis, therefore, miR-210 can be used for tumor screening, diagnosing and predicting the prognosis of patients. With the further study of downstream target gene of miR-210, the target therapy aiming at miR-210-mediated signal pathway provides a broader prospect for the treatment of malignant tumor.

     

  • 对于高危、难治或复发性急性髓系白血病(acute myeloid leukemia, AML)患者来说,异基因造血干细胞移植(allo-HSCT)可能是唯一具有治愈潜力的治疗选择[1]。尽管人类白细胞抗原(human leukocyte antigen, HLA)匹配同胞全相合供者(matched sibling donor, MSD)allo-HSCT是首选,但仅有约30%患者能够找到合适供者[2]。对于缺乏HLA匹配的患者,绝大多数都可以找到单倍体相合供者,并且单倍体相合造血干细胞移植(Haplo-HSCT)已成为广泛接受的替代方案[3]。研究表明,与MSD-HSCT相比,Haplo-HSCT能够取得相似的临床疗效[4-6]。然而,单纯外周血造血干细胞(peripheral blood stem cell, PBSC)作为移植物行Haplo-HSCT对高危及难治/复发AML患者的疗效仍不清楚。因此,本研究评估我中心以高剂量非体外去T细胞PBSC作为移植物,行Haplo-HSCT治疗高危及难治/复发AML患者的临床疗效,并与同一时期实施MSD-HSCT的结果进行比较。

    回顾性分析2010年1月至2020年6月在新疆医科大学第一附属医院血液病中心进行造血干细胞移植的成人高危及难治/复发AML患者(≥18岁)资料。患者的诊断依据为2016版WHO造血和淋巴组织肿瘤的分型诊断标准[7],高危定义如下:伴有预后差的染色体核型或分子遗传学标志;高白细胞计数 > 50×109/L;前驱血液病史;合并中枢神经系统白血病(central nervous system leukemia, CNSL)。难治、复发AML的诊断标准依据中华医学会血液学分会制定的诊断标准[8]。所有供者、患者均签署知情同意书。

    移植物均为非体外去T细胞PBSC,采用重组人粒细胞集落刺激因子(rhG-CSF)7~10 μg/(kg.d)皮下注射动员PBSC,于动员的第5、6天采集,体重过低的供者于动员第4~6天采集(供受者体重差 < 10 kg)或提前冻存干细胞(供受者体重差≥10 kg)。

    试验分为两组:Haplo-HSCT组采用阿糖胞苷(Ara-C)+白消安(Bu)+环磷酰胺(Cy)+抗胸腺细胞球蛋白(ATG)[9],MSD-HSCT组采用ABu/Cy或者ABu/Cy+ATG或者Bu/Cy+ATG方案。两组患者均采用清髓性预处理方案。

    两组患者均采用环孢素(CsA)或他克莫司(Tac)+甲氨蝶呤(MTX)+霉酚酸酯(MMF)作为基础预防方案:CsA:移植前5天至移植后30天2.5 mg/(kg.d)静脉滴注,30天后改为(4~5)mg/(kg.d)口服,或者Tac 0.02 mg/(kg.d)静脉滴注,移植30天后改为0.1 mg/(kg.d)口服,根据血药浓度调整;MTX:移植后第1天15 mg/(m2.d)静脉滴注,移植后第3天、第6天改为10 mg/(m2.d)静脉滴注;MMF:移植前1天至移植后100天1.0 g/d口服;地塞米松(Glu):移植后1天至移植后15天5 mg/d静脉滴注,之后逐渐减量,MSD组在移植后30天停用,Haplo-HSCT组用至移植后100天。Haplo-HSCT组在上述基础上加用抗CD25单克隆抗体(舒莱)移植当天及移植后第2天12 mg/m2静脉滴注。

    动态监测血常规,连续3天中性粒细胞计数绝对值(ANC)≥0.5×109/L为粒系植入时间;不输注血小板情况下血小板计数(PLT)连续7天≥20×109/L为巨核系植入时间。GVHD分级及诊断根据西雅图国际标准进行评分及分级。总生存(OS)为移植后至任何原因导致的死亡时间或随访截止时间。无病生存(DFS)为移植后至随访截止或者复发/死亡时间。

    随访资料来自电话随访、住院/门诊病历。随访截至2021年12月30日。

    采用SPSS25.0和GraphPad Prism 5.0软件进行数据分析。计数和计量资料用频率和中位数等进行描述统计。组间资料比较采用卡方检验或t检验。急性和慢性GVHD、DFS以及OS等采用Kaplan-Meier进行描述和分析。P < 0.05为差异有统计学意义。

    本研究共纳入98例患者,其中Haplo-HSCT组62例,MSD-HSCT组36例。两组中位年龄、预处理方案、MNC及CD34+细胞输注剂量差异均有统计学意义(均P < 0.05),其他临床指标差异均无统计学意义(P > 0.05),见表 1

    表  1  98例高危及难治/复发急性髓系白血病患者的临床特征
    Table  1  Clinical characteristics of 98 patients with high-risk and refractory/relapsed acute myeloid leukemia
    下载: 导出CSV 
    | 显示表格

    本研究中共有4例患者植入失败,均发生在Haplo-HSCT组,两组植入率比较差异无统计学意义(93.5% vs. 100%, P=0.120)。Haplo-HSCT组、MSD-HSCT组中性粒细胞恢复中位时间分别为16(10~21)d和15.5(11~18)d(P=0.452),血小板恢复中位时间分别为15(13~20)d和16(13~22)d(P=0.231),差异均无统计学意义。

    100天内Haplo-HSCT组、MSD-HSCT组Ⅱ~Ⅳ度急性移植物抗宿主病(acute graft- versus-host disease, aGVHD)的发生率分别为27.89%(95%CI: 15.76~40.02)和17.19%(95%CI: 4.65~29.73),两组比较差异无统计学意义(P=0.246),见图 1A。Haplo-HSCT组、MSD-HSCT组Ⅲ~Ⅳ度aGVHD的发生率分别为10.96%(95%CI: 2.60~19.11)和3.45%(95%CI: 0~10.19),两组比较差异无统计学意义(P=0.154),见图 1B

    图  1  Haplo-HSCT和MSD-HSCT组aGVHD(A, B)和cGVHD(C, D)的发生情况
    Figure  1  Occurrence of aGVHD(A, B) and cGVHD(C, D) in Haplo-HSCT and MSD-HSCT groups
    aGVHD: acute graft-versus-host disease; cGVHD: chronic graft-versus-host disease.

    Haplo-HSCT组、MSD-HSCT组慢性移植物抗宿主病(chronic graft- versus-host disease, cGVHD)的3年累积发生率分别为46.31%(95%CI: 31.86~60.76)和35.16%(95%CI: 18.13~52.19),两组相比差异无统计学意义(P=0.433),见图 1C。Haplo-HSCT组、MSD-HSCT组广泛型cGVHD的3年累积发生率分别为9.15%(95%CI: 1.43~16.87)和20.24%(95%CI: 3.29~37.19),两组比较差异无统计学意义(P=0.473),见图 1D

    随访期间,Haplo-HSCT组有10例患者复发,其中2例为髓外复发,复发部位分别为淋巴结和中枢神经系统,余8例为骨髓复发。MSD-HSCT组有14例患者复发,其中3例为髓外复发,复发部位分别为腮腺、肝脏和中枢神经系统,余11例为骨髓复发。两组患者3年累积复发率分别为16.2%(95%CI: 5.42~26.98)和41.1%(95%CI: 23.66~58.54),两组相比差异有统计学意义(P=0.036),见图 2A。两组患者3年非复发死亡率(NRM)分别为16.61%(95%CI: 7.18~26.04)和21.71%(95%CI: 3.13~40.29),两组相比差异无统计学意义(P=0.689),见图 2B

    图  2  两组患者的累积复发率(A)和非复发死亡率(B)
    Figure  2  Cumulative relapse rate(A) and non-relapse mortality(B) of the two groups of patients

    本研究中主要并发症为移植后感染,多为细菌和(或)真菌感染,两组相比差异无统计学意义(P=0.129)。28例患者发生出血性膀胱炎,其中Haplo-HSCT组22例、MSD-HSCT组6例,两组相比差异无统计学意义(P=0.063)。两组患者发生间质性肺炎、带状疱疹和CMV血症的差异均无统计学意义,见表 2

    表  2  高危及难治/复发的AML患者移植后并发症
    Table  2  Post-transplantation complications in patients with high-risk and refractory/relapsed acute myeloid leukemia
    下载: 导出CSV 
    | 显示表格

    本研究中位随访时间为27(2~119)月。Haplo-HSCT组有17例患者死亡,5人死于复发,8人死于感染,3人死于植入失败,1人死于呼吸循环衰竭。MSD-HSCT组有17例患者死亡,其中9人死于复发,4人死于感染,4人死于脑出血。Haplo-HSCT组、MSD-HSCT组3年DFS率分别为66.98(95%CI: 53.87~80.09)和41.8%(95%CI: 24.1~59.5),两组相比差异无统计学意义(P=0.140),见图 3A。Haplo-HSCT组、MSD-HSCT组3年OS率分别为73.37%(95%CI 61.55~85.19)和51.41%(95%CI: 33.59~69.23),两组相比差异无统计学意义(P=0.105),见图 3B。对可能影响患者预后的因素如患者年龄、供者年龄、供-受者性别匹配、是否发生aGVHD、是否发生cGVHD、输注MNC剂量、输注CD34+细胞剂量等进行多因素Cox回归分析,未发现影响患者生存的独立危险因素,见表 3

    图  3  两组患者的DFS(A)和OS(B)分析
    Figure  3  DFS(A) and OS(B) analysis of the two groups of patients
    表  3  98例患者DFS和OS影响因素的多因素分析
    Table  3  Multivariate analysis of risk factors related to DFS and OS of 98 patients
    下载: 导出CSV 
    | 显示表格

    AML是成人最常见的恶性血液病,尽管目前对初诊患者诱导化疗后完全缓解(CR)率可达60%~80%,但对高危以及复发/难治AML患者的疗效仍欠佳[10]。Allo-HSCT是AML患者的最佳潜在治疗方法,尤其是细胞遗传学不良且单独化疗预后非常差的患者[11]。因此,选择合适的移植方式对患者的治疗策略至关重要。

    最近,Haplo-HSCT的数量逐渐增加,并取得了不错的效果。越来越多的研究表明,对于AML患者接受Haplo-HSCT与MSD-HSCT疗效相当[12-14]。然而,对于Haplo-HSCT在治疗复发/难治性AML中是否存在与MSD-HSCT同等的疗效,目前相关报道较少。来自欧洲血液和骨髓移植学会(EBMT)的一项研究表明,在中度或高风险细胞遗传学首次完全缓解的AML患者中,Haplo-HSCT与MSD-HSCT的疗效相似[11]。本研究中也取得了类似结果,Haplo-HSCT与MSD-HSCT在植入、GVHD、DFS及OS方面的差异无统计学意义。然而,最近一项研究通过比较Haplo-HSCT与MSD在复发/难治性AML患者的预后发现Haplo-HSCT后OS、DFS较低,NRM较高,导致患者预后较差[15]。不同研究中心取得不同的结果可能与患者类型及移植体系有关。

    Haplo-HSCT因供受体之间的HLA差异引起双向免疫屏障,导致发生原发性移植失败的倾向更高。本研究中,Haplo-HSCT组均输注高剂量非体外去T细胞PBSC作为移植物,以克服免疫屏障,促进持续稳定的植入。但是随着输注剂量的增加,GVHD的发生风险也随之增加。我们在经典的GVHD预防方案中添加了抗CD25单克隆抗体(舒莱)及短程低剂量的糖皮质激素以加强GVHD预防。由此,形成本血液病中心独特的移植体系-高剂量非体外去T细胞PBSC作为移植物联合强化的GVHD预防方案。抗CD25单克隆抗体能够抑制同种抗原诱导的T细胞增殖以及抗原特异性细胞毒性T细胞的生成,降低GVHD的发生[16]。Chang等[17]研究表明低剂量糖皮质激素能够显著降低aGVHD的发生率,并在不增加感染的情况下减少不良事件的发生。本研究结果表明,两组间GVHD的发生率比较差异无统计学意义,但是Haplo-HSCT广泛型cGVHD发生率有降低的趋势(9.15% vs. 20.24%, P=0.473),考虑可能与我们强化的GVHD预防方案有关。两组患者移植后并发症的比较未发现显著性差异,提示强化的GVHD预防方案并未增加感染的风险。

    近年来,越来越多的研究显示Haplo-HSCT治疗恶性血液病较MSD-HSCT具有更强的移植物抗白血病(GVL)作用。Yu等[18]通过前瞻性多中心的研究表明,Haplo-HSCT治疗首次完全缓解的高风险AML与MSD-HSCT相比复发率更低,提示Haplo-HSCT可能存在更强的GVL效应。本研究中也得到了一致结果,Haplo-HSCT组3年累积复发率显著低于MSD-HSCT组。Guo等[19]通过动物模型发现Haplo-HSCT存在更强GVL作用,是因为自然杀伤(NK)细胞凋亡减少和细胞毒性细胞因子分泌增加。此外,从理论上来看,Haplo-HSCT存在更强GVL效应可通过降低NRM从而提高存活率[20]。本研究中两组的生存情况并无差异,多因素分析也并未发现影响患者预后的危险因素,这可能与样本量较少有关。

    总之,本研究初步表明对高危以及复发/难治AML患者接受Haplo-HSCT与MSD-HSCT疗效相似,且haplo-HSCT的复发率更低,可能存在更强的GVL效应。但本研究为回顾性研究且病例数较少,后期仍需要进行前瞻性大样本研究进一步证实此结论。

  • [1]

    Bensaad K, Harris AL. Hypoxia and metabolism in cancer[J]. Adv Exp Med Biol, 2014, 772: 1-39. doi: 10.1007/978-1-4614-5915-6

    [2]

    Qin Q, Furong W, Baosheng L. Multiple functions of hypoxia-regulated miR-210 in cancer[J]. J Exp Clin Cancer Res, 2014, 33:50. doi: 10.1186/1756-9966-33-50

    [3]

    Nijhuis A, Thompson H, Adam J, et al. Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance[J]. Hum Mol Genet, 2017, 26(8): 1552-64. doi: 10.1093/hmg/ddx059

    [4]

    Hall JS, Taylor J, Valentine HR, et al. Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation[J]. Br J Cancer, 2012, 107(4):684-94. doi: 10.1038/bjc.2012.294

    [5]

    Qu A, Du L, Yang Y, et al. Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer[J]. PLoS One, 2014, 9(3): e90952. doi: 10.1371/journal.pone.0090952

    [6]

    Rutnam ZJ, Wight TN, Yang BB. miRNAs regulate expression and function of extracellular matrix molecules[J]. Matrix Biol J Inter Society Matrix Biol, 2013, 32(2): 74-85. doi: 10.1016/j.matbio.2012.11.003

    [7]

    Chang W, Chang YL, Park JH, et al. Survival of hypoxic human mesenchymal stem cells is enhanced by a positive feedback loop involving miR-210 and hypoxia-inducible factor 1[J]. J Vet Sci, 2013, 14(1):69-76. doi: 10.4142/jvs.2013.14.1.69

    [8]

    Devlin C, Greco S, Martelli F, et al. miR-210: More than a Silent Player in Hypoxia[J]. IUBMB Life, 2011, 63(2):94-100. http://cn.bing.com/academic/profile?id=0bd173f0982b4f8b50dab9fc7c0103d3&encoded=0&v=paper_preview&mkt=zh-cn

    [9]

    Chen Z, Li Y, Zhang H, et al. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression[J]. Oncogene, 2010, 29(30): 4362-8. doi: 10.1038/onc.2010.193

    [10]

    HuangX, Le QT, Giaccia AJ. MiR-210 micromanager of the hypoxia pathway[J]. Trends Mol Med, 2010, 16(5): 230-7. doi: 10.1016/j.molmed.2010.03.004

    [11]

    Tadokoro H, Umezu T, Ohyashiki K, et al. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells[J]. J Biol Chem, 2013, 288(48): 34343-51. doi: 10.1074/jbc.M113.480822

    [12]

    Yang Y, Zhang J, Xia T, et al. MicroRNA-210 promotes cancer angiogenesis by targeting fibroblast growth factor receptor-like 1 in hepatocellular carcinoma[J]. Oncol Rep, 2016, 36(5): 2553-62. doi: 10.3892/or.2016.5129

    [13]

    Cui H, Seubert B, Stahl E, et al. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes[J]. Oncogene, 2015, 34(28): 3640-50. doi: 10.1038/onc.2014.300

    [14]

    Tsuchiya S, Fujiwara T, Sato F, et al. MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1)[J]. J Biol Chem, 2011, 286(1): 420-8. doi: 10.1074/jbc.M110.170852

    [15]

    Mei XS, Hu HY, Nie GH. MiR-210 regulates cell cycle in nasopharyngeal carcinoma cell line (CNE-1) under hypoxic condition by reducing the expression of cyclin D1[J]. Chinese-German J Clin Oncol, 2014, 13(7): 323-7. http://cn.bing.com/academic/profile?id=8fa80c8bfcfeabea8f394af5b3524e4e&encoded=0&v=paper_preview&mkt=zh-cn

    [16]

    Noman MZ, Buart S, Romero P, et al. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells[J]. Cancer Res, 2012, 72(18): 4629-41. doi: 10.1158/0008-5472.CAN-12-1383

    [17]

    Yoshioka Y, Kosaka N, Ochiya T, et al. Micromanaging Iron Homeostasis[J]. J Biol Chem, 2012, 287(41): 34110 -9. doi: 10.1074/jbc.M112.356717

    [18]

    Bavelloni A, Poli A, Fiume R, et al. PLC-beta 1 regulates the expression of miR-210 during mithramycin-mediated erythroid differentiation in K562 cells[J]. Oncotarget, 2014, 5(12): 4222-31. http://cn.bing.com/academic/profile?id=81d3a0c1f2f0e8eed4453568c4b5b4c3&encoded=0&v=paper_preview&mkt=zh-cn

    [19]

    Zhang H, Mai Q, Chen J. MicroRNA-210 is increased and it is required for dedifferentiation of osteosarcoma cell line[J]. Cell Biol Inter, 2017, 41(3): 267-75. doi: 10.1002/cbin.v41.3

    [20]

    Grosso S, Doyen J, Parks SK, et al. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines[J]. Cell Death Dis, 2013, 4: e544. doi: 10.1038/cddis.2013.71

    [21]

    Mei Y, Gao C, Wang K, et al. Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia[J]. Cancer Sci, 2014, 105(4): 463-72. doi: 10.1111/cas.2014.105.issue-4

    [22]

    Yang W, Wei J, Sun T, et al. Effects of knockdown of miR-210 in combination with ionizing radiation on human hepatoma xenograft in nude mice[J]. Radiat Oncol, 2013, 8: 102. doi: 10.1186/1748-717X-8-102

    [23]

    Liu TY, Zhang H, Du SM, et al. Expression of microRNA-210 in tissue and serum of renal carcinoma patients and its effect on renal carcinoma cell proliferation, apoptosis, and invasion[J]. Genet Mol Res, 2016, 15(1): 15017746. http://cn.bing.com/academic/profile?id=ec8d3d03d77a9371b700a4055a7b80ed&encoded=0&v=paper_preview&mkt=zh-cn

    [24]

    Wang F, Xiong L, Huang X, et al. miR-210 suppresses BNIP3 to protect against the apoptosis of neural progenitor cells[J]. Stem Cell Res, 2013, 11(1): 657-67. doi: 10.1016/j.scr.2013.04.005

    [25]

    Zhang S, Lai N, Liao K, et al. MicroRNA-210 regulates cell proliferation and apoptosis by targeting regulator of differentiation 1 in glioblastoma cells[J]. Folia Neuropathol, 2015, 53(3): 236-44. http://cn.bing.com/academic/profile?id=57407c0eef126623ed8c73ada26a3292&encoded=0&v=paper_preview&mkt=zh-cn

    [26]

    Shang C, Hong Y, Guo Y, et al. MiR-210 Up-Regulation Inhibits Proliferation and Induces Apoptosis in Glioma Cells by Targeting SIN3A[J]. Med Sci Monit, 2014, 20:2571-7. http://cn.bing.com/academic/profile?id=3404ff41613101f97b42fb5a74aeddd6&encoded=0&v=paper_preview&mkt=zh-cn

    [27]

    Chio CC, Lin JW, Cheng HA, et al. MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells[J]. Arch Toxicol, 2013, 87(3): 459-68. doi: 10.1007/s00204-012-0965-5

    [28]

    He J, Wu J, Xu N, et al. MiR-210 disturbs mitotic progression through regulating a group of mitosis-related genes[J]. Nucleic Acids Res, 2013, 41(1):498-508. doi: 10.1093/nar/gks995

    [29]

    Sauermann M, Sahin O, Sültmann H, et al. Reduced expression of vacuole membrane protein 1 affects the invasion capacity of tumor cells[J]. Oncogene, 2008, 27(9): 1320-6. doi: 10.1038/sj.onc.1210743

    [30]

    Qu A, Du L, Yang Y, et al. Hypoxia-Inducible MiR-210 Is an Independent Prognostic Factor and Contributes to Metastasis in Colorectal Cancer[J]. PLoS One, 2014, 9(3): e90952. doi: 10.1371/journal.pone.0090952

    [31]

    Ren D, Yang Q, Dai Y, et al. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway[J]. Mol Cancer, 2017, 16(1): 117. doi: 10.1186/s12943-017-0688-6

    [32]

    Kai AK, Chan LK, Lo RC, et al. Down-regulation of TIMP2 by HIF-1α/miR-210/HIF-3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma[J]. Hepatology, 2016, 64(2): 473-87. doi: 10.1002/hep.28577

    [33]

    Tang X, Chen L, Yan X, et al. Overexpression of miR-210 is Associated with Poor Prognosis of Acute Myeloid Leukemia[J]. Med Sci Monitor Inter Med J Exp Clin Res, 2015, 21: 3427-33. doi: 10.12659/MSM.894812

    [34]

    Lai NS, Wu DG, Fang XG, et al. Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma[J]. Br J Cancer, 2015, 112(7): 1241-6. doi: 10.1038/bjc.2015.91

    [35]

    Li M, Ma X, Li M, et al. Prognostic role of microRNA-210 in various carcinomas: a systematic review and meta-analysis[J]. Dis Markers, 2014, 2014: 106197. http://cn.bing.com/academic/profile?id=316f730f05e148fa13722937b4edcb66&encoded=0&v=paper_preview&mkt=zh-cn

    [36]

    Ono S, Oyama T, Lam S, et al. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients[J]. Oncotarget, 2015, 6(9): 7053-64. http://cn.bing.com/academic/profile?id=202e57308ebe10b4fc46f496880dfead&encoded=0&v=paper_preview&mkt=zh-cn

    [37]

    Yang Y, Qu A, Liu J, et al. Serum miR-210 Contributes to Tumor Detection, Stage Prediction and Dynamic Surveillance in Patients with Bladder Cancer[J]. PLoS One, 2015, 10(8): e0135168. doi: 10.1371/journal.pone.0135168

    [38]

    Lai N, Zhu H, Chen Y, et al. Differential expression of microRNA-210 in gliomas of variable cell origin and correlation between increased expression levels and disease progression in astrocytic tumours.[J]. Folia Neuropathologica, 2014, 52(1): 79-85. http://cn.bing.com/academic/profile?id=1f992d9c8257438daece81b8d868635b&encoded=0&v=paper_preview&mkt=zh-cn

    [39]

    Yang W, Sun T, Cao J, et al. Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro[J]. Exp Cell Res, 2012, 318(8): 944-54. doi: 10.1016/j.yexcr.2012.02.010

  • 期刊类型引用(0)

    其他类型引用(1)

计量
  • 文章访问数:  1710
  • HTML全文浏览量:  402
  • PDF下载量:  666
  • 被引次数: 1
出版历程
  • 收稿日期:  2017-12-18
  • 修回日期:  2018-03-28
  • 网络出版日期:  2024-01-12
  • 刊出日期:  2018-07-24

目录

/

返回文章
返回
x 关闭 永久关闭